Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.6% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.23. 15,196,699 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 60,758,266 shares. The stock had previously closed at $0.24.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Friday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 2.8 %

The firm has a market capitalization of $42.80 million, a P/E ratio of 0.00 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a 50-day moving average of $0.26 and a 200-day moving average of $0.29.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.